Amyotrophic lateral sclerosis (ALS) is a degenerative disease of motor neurons that inexorably leads to progressive weakness and death. There is no specific biomarker for this disease, and the diagnosis is often delayed as clinical and electrophysiological examinations are often inconclusive in the early stages. Furthermore, once a diagnosis is established, the current tools to track patients are insensitive for the timely detection of disease improvement or worsening. A biomarker that can facilitate diagnosis, track disease progression, or both, would fill a large clinical gap in ALS management, and expedite clinical trials of novel therapies. The long term goal of this application is to identify molecular signatures in muscle of ALS patients that can serve as disease biomarkers. In ALS, changes occur in skeletal muscle prior to motor neuron death and clinical onset, such as structural changes in the neuromuscular junction, muscle restricted mitochondrial dysfunction, and fiber atrophy. Muscle is the """"""""end organ"""""""" affected by the degenerative process of ALS and is the most accessible for molecular study. Here we hypothesize that gene expression patterns in muscle from patients with ALS contain molecular signatures that can serve as biomarkers of the disease. This hypothesis is based on preliminary data we obtained using next generation deep sequencing on muscle samples of clinically well characterized ALS patients. Using non-ALS disease- and normal control samples, we identified over 300 unique targets in ALS samples, including isoform variances, that will serve as the basis of study for this application. We are wel positioned to carry out this study because of the large neuromuscular patient population, including ALS and ALS mimics, and our oversight of the electrodiagnostic and muscle histology laboratories. Here, we will further investigate our molecular targets with the following two specific aims:
Specific Aims : 1. To validate ALS-specific targets and isoform variances identified by deep sequencing by performing PCR analysis of a large cohort of ALS and non-ALS muscle samples. 2: To assess protein expression of validated targets in muscle tissues from ALS patients and correlate targets with muscle samples from the G93A SOD1 ALS mouse.

Public Health Relevance

Amyotrophic lateral sclerosis is a fatal degenerative disease of motor neurons. There are currently no biomarkers that can facilitate early diagnosis or track progression of the disease. This application will investigate molecular signatures in muscle as biomarkers of ALS, and thus may fill this void and improve disease management and assessment of novel therapies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21NS085497-02
Application #
8722055
Study Section
Clinical Neuroscience and Neurodegeneration Study Section (CNN)
Program Officer
Gubitz, Amelie
Project Start
2013-09-01
Project End
2015-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Neurology
Type
Schools of Medicine
DUNS #
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Si, Ying; Cui, Xianqin; Crossman, David K et al. (2018) Muscle microRNA signatures as biomarkers of disease progression in amyotrophic lateral sclerosis. Neurobiol Dis 114:85-94
Ardelt, A; Carpenter, R; Iwuchukwu, I et al. (2018) Characterization of the transient middle cerebral artery occlusion model of ischemic stroke in a HuR transgenic mouse line. Data Brief 16:1083-1090
Ardelt, Agnieszka A; Carpenter, Randall S; Iwuchukwu, Ifeanyi et al. (2017) Transgenic expression of HuR increases vasogenic edema and impedes functional recovery in rodent ischemic stroke. Neurosci Lett 661:126-131
Si, Ying; Kim, Soojin; Cui, Xiangqin et al. (2015) Transforming Growth Factor Beta (TGF-?) Is a Muscle Biomarker of Disease Progression in ALS and Correlates with Smad Expression. PLoS One 10:e0138425
Si, Ying; Cui, Xianqin; Kim, Soojin et al. (2014) Smads as muscle biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 1:778-87
Lu, Liang; Zheng, Lei; Si, Ying et al. (2014) Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-43 and FUS/TLS: implications for amyotrophic lateral sclerosis. J Biol Chem 289:31792-804